Decision XII/2.  Measures to facilitate the transition to
chlorofluorocarbon-free

metered-dose inhalers

For the purposes of this decision, "chlorofluorocarbon metered-dose
inhaler product" means a chlorofluorocarbon-containing metered-dose
inhaler of a particular brand name or company, active ingredient(s) and
strength;

That any chlorofluorocarbon metered-dose inhaler product approved after
31 December 2000 for treatment of asthma and/or chronic obstructive
pulmonary disease in a non-Article 5(1) Party is not an essential use
unless the product meets the criteria set out in paragraph 1(a) of
decision IV/25;

With respect to any chlorofluorocarbon metered-dose inhaler active
ingredient or category of products that a Party has determined to be
non-essential and thereby not authorized for domestic use, to request: 

The Party that has made the determination to notify the Secretariat;

(b)	The Secretariat to maintain such a list on its Web site; 

(c)	Each nominating Party to reduce accordingly the volume of
chlorofluorocarbons it requests and licenses;

4.	To encourage each Party to urge each metered-dose inhaler company
within its territory to diligently seek approval for the company's
chlorofluorocarbon-free alternatives in its domestic and export markets,
and to require each Party to provide a general report on such efforts to
the Secretariat by 31 January 2002 and each year thereafter; 

5.	To agree that each non-Article 5 Party should, if it has not already
done so:

Develop a national or regional transition strategy based on economically
and technically feasible alternatives or substitutes that it deems
acceptable from the standpoint of environment and health and that
includes effective criteria and measures for determining when
chlorofluorocarbon metered-dose inhaler product(s) is/are no longer
essential;

Submit the text of any such strategy to the Secretariat by 31 January
2002; 

Report to the Secretariat by 31 January each year thereafter on progress
made on its transition to chlorofluorocarbon-free metered-dose inhalers;


6.	To encourage each Article 5(1) Party to:

(a)	Develop a national or regional transition strategy based on
economically and technically feasible alternatives or substitutes that
it deems acceptable from the standpoint of environment and health and
that includes effective criteria and measures for determining when
chlorofluorocarbon metered-dose inhaler product(s) can be replaced with
chlorofluorocarbon-free alternatives;

(b)	Submit the text of any such a strategy to the Secretariat by 31
January 2005; 

(c)	Report to the Secretariat by 31 January each year thereafter on
progress made on its transition to chlorofluorocarbon-free metered-dose
inhalers; 

7.	To request the Executive Committee of the Multilateral Fund to
consider providing technical, financial and other assistance to Article
5(1) Parties to facilitate the development of metered-dose inhaler
transition strategies and the implementation of approved activities
contained therein, and to invite the Global Environment Facility to
consider providing the same assistance to those eligible countries with
economies in transition;

8.	To decide that, as a means of avoiding unnecessary production of new
chlorofluorocarbons, and provided that the conditions set out in
paragraphs (a) - (d) of decision IX/20 are met, a Party may allow a
metered-dose inhaler company to transfer: 

All or part of its essential use authorization to another existing
metered-dose inhaler company; or 

	Chlorofluorocarbons to another metered-dose inhaler company provided
that the transfer complies with national/regional licence or other
authorization requirements;

9.	To request the Technology and Economic Assessment Panel to summarize
and review by 15 May each year the information submitted to the
Secretariat;

10.	To modify as necessary the Handbook for Essential Use Nominations to
take account of the requirements contained in this decision as they
pertain to non-Article 5(1) Parties;

11.	To request the Technology and Economic Assessment Panel to consider
and report to the next Meeting of the Parties on issues related to the
campaign production of chlorofluorocarbons for chlorofluorocarbon
metered-dose inhalers. 

